Literature DB >> 16476980

Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease.

Anna Laurén1, Rigmor Thorstensson2, Eva Maria Fenyö1.   

Abstract

The kinetics of appearance of autologous neutralizing antibodies were studied in cynomolgus macaques infected with simian immunodeficiency virus (SIVsm) by the intravenous (IV) route (six monkeys) or the intrarectal (IR) route (ten monkeys). The SIVsm inoculum virus and reisolates obtained at 2 weeks, 3 or 4 months and later than 1 year were tested in a GHOST(3) cell line-based plaque-reduction assay with autologous sera collected at the same sampling times. All monkeys developed a neutralizing-antibody response to the inoculum virus, those infected by the IV route earlier than monkeys infected by the IR route. Animals were divided into progressor (P), slow-progressor (SP) and long-term non-progressor (LTNP) monkeys, based on progression rate. In P monkeys, neutralization escape could be demonstrated by 3 months post-infection. Neutralization-resistant variants also emerged in SP and LTNP monkeys, but were much delayed compared with P monkeys. Evolution of neutralization resistance was also demonstrated by a positive-control serum in the heterologous reaction. Pooled sera from four LTNP monkeys showed a broad neutralizing capacity, including neutralization of escape variants. These results from a large group of infected monkeys showed that SIV evolves to neutralization resistance in the infected host and that the kinetics of this evolution are related to the route of transmission and the progression rate of SIV disease. The results suggest an important role for neutralizing antibodies in controlling viraemia. Although this control is transient in the infected host, neutralization resistance is relative and variant viruses may be neutralized by a broadly cross-neutralizing serum pool.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476980     DOI: 10.1099/vir.0.81409-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.

Authors:  Gülşen Özkaya Şahin; Fredrik Månsson; Angelica A Palm; Elzbieta Vincic; Zacarias da Silva; Patrik Medstrand; Hans Norrgren; Eva Maria Fenyö; Marianne Jansson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-11-21       Impact factor: 2.205

2.  International network for comparison of HIV neutralization assays: the NeutNet report II.

Authors:  Leo Heyndrickx; Alan Heath; Enas Sheik-Khalil; Jose Alcami; Vera Bongertz; Marianne Jansson; Mauro Malnati; David Montefiori; Christiane Moog; Lynn Morris; Saladin Osmanov; Victoria Polonis; Meghna Ramaswamy; Quentin Sattentau; Monica Tolazzi; Hanneke Schuitemaker; Betty Willems; Terri Wrin; Eva Maria Fenyö; Gabriella Scarlatti
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

3.  Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.

Authors:  Gülşen Ozkaya Sahin; Emma J Bowles; Joe Parker; Hannes Uchtenhagen; Enas Sheik-Khalil; Stephen Taylor; Oliver G Pybus; Barbro Mäkitalo; Lilian Walther-Jallow; Mats Spångberg; Rigmor Thorstensson; Adnane Achour; Eva Maria Fenyö; Guillaume B E Stewart-Jones; Anna-Lena Spetz
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

4.  HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine Development.

Authors:  Batul Diwan; Rupali Saxena; Archana Tiwari
Journal:  Springerplus       Date:  2013-01-11

5.  CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates.

Authors:  Anna Laurén; Elzbieta Vincic; Hiroo Hoshino; Rigmor Thorstensson; Eva Maria Fenyö
Journal:  Retrovirology       Date:  2007-07-23       Impact factor: 4.602

6.  Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition.

Authors:  Enas Sheik-Khalil; Mark-Anthony Bray; Gülsen Özkaya Şahin; Gabriella Scarlatti; Marianne Jansson; Anne E Carpenter; Eva Maria Fenyö
Journal:  BMC Infect Dis       Date:  2014-08-30       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.